<p>根据 Marketbeat.com 的报道，Spyre Therapeutics, Inc.（NASDAQ:SYRE - 获取免费报告）的股票获得了目前覆盖该公司的十一家评级公司的共识评级为 “买入”。一名股票研究分析师对该股票给予了卖出建议，七名分析师发出了买入建议，三名分析师则给予了强烈买入建议。在过去一年中，发布报告的经纪公司对该股票的平均 12 个月目标价格为 53.8750 美元。</p>
<p>获取 <strong>Spyre Therapeutics</strong> 的提醒：</p>
<p>一些研究公司最近对 SYRE 发表了评论。瑞穗证券在 12 月 18 日的报告中将 Spyre Therapeutics 的股票评级上调至 “强烈买入”。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Spyre Therapeutics 的 “卖出（e+）” 评级。Jones Trading 在 12 月 1 日的研究报告中将 Spyre Therapeutics 的股票评级从 “持有” 上调至 “买入”，并设定了 64.00 美元的目标价格。BTIG Research 在 9 月 16 日的报告中重申了 “买入” 评级，并对 Spyre Therapeutics 的股票设定了 70.00 美元的目标价格。最后，德意志银行在 9 月 26 日的研究报告中开始覆盖 Spyre Therapeutics，并对该股票给予了 “买入” 评级和 43.00 美元的目标价格。</p>
<p><strong>查看我们最新的 SYRE 股票分析</strong></p>
<h2>Spyre Therapeutics 股票表现</h2>
<p>NASDAQ SYRE 的股票在周四以 31.05 美元开盘。Spyre Therapeutics 的 52 周低点为 10.91 美元，52 周高点为 35.31 美元。该公司的市值为 24.1 亿美元，市盈率为-14.18，贝塔值为 3.17。该公司的 50 日移动平均价格为 29.13 美元，200 日移动平均价格为 21.39 美元。</p>
<p>Spyre Therapeutics（NASDAQ:SYRE - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为-0.15 美元，超出分析师的共识预期（-0.68 美元）0.53 美元。卖方分析师预测 Spyre Therapeutics 在当前年度的每股收益为-4.46 美元。</p>
<h2>Spyre Therapeutics 的内部活动</h2>
<p>在相关消息中，首席执行官 Cameron Turtle 在 11 月 3 日的交易中出售了 45,000 股 Spyre Therapeutics 的股票。该股票以平均价格 23.33 美元出售，总价值为 1,049,850.00 美元。出售完成后，首席执行官直接持有该公司 701,907 股股票，价值 16,375,490.31 美元。此次交易使其持股比例减少了 6.02%。该交易已在 SEC 的法律文件中披露，相关信息可通过 SEC 网站获取。在过去 90 天内，内部人士共出售了 75,000 股公司股票，价值 1,945,350 美元。公司内部人士持有公司股票的 15.43%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近增加或减少了对该公司的持股。Wellington Management Group LLP 在第三季度将其在 Spyre Therapeutics 的持股比例提高了 8.4%。Wellington Management Group LLP 目前持有该公司 1,640,312 股股票，价值 27,492,000 美元，在此期间又购买了 126,834 股。Jefferies Financial Group Inc.在第二季度将其在 Spyre Therapeutics 的持股比例提高了 11.2%。Jefferies Financial Group Inc.目前持有该公司 1,388,854 股股票，价值 20,791,000 美元，在上个季度又购买了 140,000 股。Geode Capital Management LLC 在第二季度将其在 Spyre Therapeutics 的持股比例提高了 15.8%。Geode Capital Management LLC 目前持有该公司 1,227,232 股股票，价值 18,373,000 美元，在上个季度又购买了 167,669 股。TCG Crossover Management LLC 在第三季度购买了 Spyre Therapeutics 的新股份，价值 18,446,000 美元。最后，Baker BROS. Advisors LP 在第三季度将其在 Spyre Therapeutics 的持股比例提高了 59.6%。Baker BROS. Advisors LP 目前持有该公司 1,000,000 股股票，价值 16,760,000 美元，在上个季度又购买了 373,297 股。对冲基金和其他机构投资者持有公司 80.39% 的股票。</p>
<h2>关于 Spyre Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Spyre Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于癌症新型免疫疗法的发现和开发。该公司利用专有的蛋白质工程和生物制剂设计平台，创造旨在增强抗肿瘤免疫反应和抑制肿瘤生长的靶向分子。其临床前管线包括多个针对实体肿瘤和血液肿瘤适应症的候选疗法。</p>
<p>Spyre Therapeutics 由一支在蛋白质设计、免疫学和转化研究方面具有深厚专业知识的团队成立，致力于与领先的学术机构和研究组织合作，加速其发现工作。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Spyre Therapeutics</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 上市！100 美元的 IPO 前机会！</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUX8mU3ltYm9sPVNZUkU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUX8mU3ltYm9sPVNZUkU"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Spyre Therapeutics 吗？</h2>
<p>在考虑 Spyre Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Spyre Therapeutics 并不在名单上。</p>
<p>虽然 Spyre Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SYRE

<p>Spyre Therapeutics, Inc.（纳斯达克代码：SYRE）获得了十一家券商的 “买入” 共识评级，其中包括一项卖出评级、七项买入评级和三项强力买入评级。平均 12 个月目标价格为 53.88 美元。最近的评级包括瑞穗证券的强力买入和琼斯交易的买入，目标价为 64.00 美元。该股票开盘价为 31.05 美元，52 周区间为 10.91 美元至 35.31 美元。首席执行官 Cameron Turtle 最近出售了 45,000 股，持股量减少至 701,907 股。机构投资者持有该股票的 80.39%</p>

<p>Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have been given a consensus rating of &#34;Buy&#34; by the eleven ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $53.8750.</p>
<div class="lb-trans"><p>根据 Marketbeat.com 的报道，Spyre Therapeutics, Inc.（NASDAQ:SYRE - 获取免费报告）的股票获得了目前覆盖该公司的十一家评级公司的共识评级为 “买入”。一名股票研究分析师对该股票给予了卖出建议，七名分析师发出了买入建议，三名分析师则给予了强烈买入建议。在过去一年中，发布报告的经纪公司对该股票的平均 12 个月目标价格为 53.8750 美元。</p>
</div><p>Get <strong>Spyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Spyre Therapeutics</strong> 的提醒：</p>
</div><p>A number of research firms have recently commented on SYRE. Mizuho upgraded shares of Spyre Therapeutics to a &#34;strong-buy&#34; rating in a report on Thursday, December 18th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. Jones Trading raised shares of Spyre Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $64.00 target price on the stock in a research report on Monday, December 1st. BTIG Research reiterated a &#34;buy&#34; rating and issued a $70.00 price target on shares of Spyre Therapeutics in a report on Tuesday, September 16th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Spyre Therapeutics in a research note on Friday, September 26th. They issued a &#34;buy&#34; rating and a $43.00 price objective on the stock.</p>
<div class="lb-trans"><p>一些研究公司最近对 SYRE 发表了评论。瑞穗证券在 12 月 18 日的报告中将 Spyre Therapeutics 的股票评级上调至 “强烈买入”。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Spyre Therapeutics 的 “卖出（e+）” 评级。Jones Trading 在 12 月 1 日的研究报告中将 Spyre Therapeutics 的股票评级从 “持有” 上调至 “买入”，并设定了 64.00 美元的目标价格。BTIG Research 在 9 月 16 日的报告中重申了 “买入” 评级，并对 Spyre Therapeutics 的股票设定了 70.00 美元的目标价格。最后，德意志银行在 9 月 26 日的研究报告中开始覆盖 Spyre Therapeutics，并对该股票给予了 “买入” 评级和 43.00 美元的目标价格。</p>
</div><p><strong>View Our Latest Stock Analysis on SYRE</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 SYRE 股票分析</strong></p>
</div><h2>Spyre Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Spyre Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ SYRE opened at $31.05 on Thursday. Spyre Therapeutics has a fifty-two week low of $10.91 and a fifty-two week high of $35.31. The company has a market cap of $2.41 billion, a price-to-earnings ratio of -14.18 and a beta of 3.17. The business's 50 day moving average price is $29.13 and its 200-day moving average price is $21.39.</p>
<div class="lb-trans"><p>NASDAQ SYRE 的股票在周四以 31.05 美元开盘。Spyre Therapeutics 的 52 周低点为 10.91 美元，52 周高点为 35.31 美元。该公司的市值为 24.1 亿美元，市盈率为-14.18，贝塔值为 3.17。该公司的 50 日移动平均价格为 29.13 美元，200 日移动平均价格为 21.39 美元。</p>
</div><p>Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.53. Sell-side analysts predict that Spyre Therapeutics will post -4.46 earnings per share for the current year.</p>
<div class="lb-trans"><p>Spyre Therapeutics（NASDAQ:SYRE - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为-0.15 美元，超出分析师的共识预期（-0.68 美元）0.53 美元。卖方分析师预测 Spyre Therapeutics 在当前年度的每股收益为-4.46 美元。</p>
</div><h2>Insider Activity at Spyre Therapeutics</h2>
<div class="lb-trans"><h2>Spyre Therapeutics 的内部活动</h2>
</div><p>In related news, CEO Cameron Turtle sold 45,000 shares of Spyre Therapeutics stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $23.33, for a total value of $1,049,850.00. Following the completion of the sale, the chief executive officer directly owned 701,907 shares in the company, valued at $16,375,490.31. The trade was a 6.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 75,000 shares of company stock worth $1,945,350 in the last 90 days. Company insiders own 15.43% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Cameron Turtle 在 11 月 3 日的交易中出售了 45,000 股 Spyre Therapeutics 的股票。该股票以平均价格 23.33 美元出售，总价值为 1,049,850.00 美元。出售完成后，首席执行官直接持有该公司 701,907 股股票，价值 16,375,490.31 美元。此次交易使其持股比例减少了 6.02%。该交易已在 SEC 的法律文件中披露，相关信息可通过 SEC 网站获取。在过去 90 天内，内部人士共出售了 75,000 股公司股票，价值 1,945,350 美元。公司内部人士持有公司股票的 15.43%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in shares of Spyre Therapeutics by 8.4% in the 3rd quarter. Wellington Management Group LLP now owns 1,640,312 shares of the company's stock worth $27,492,000 after purchasing an additional 126,834 shares during the period. Jefferies Financial Group Inc. raised its stake in Spyre Therapeutics by 11.2% in the second quarter. Jefferies Financial Group Inc. now owns 1,388,854 shares of the company's stock worth $20,791,000 after buying an additional 140,000 shares in the last quarter. Geode Capital Management LLC raised its stake in Spyre Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,227,232 shares of the company's stock worth $18,373,000 after buying an additional 167,669 shares in the last quarter. TCG Crossover Management LLC purchased a new stake in Spyre Therapeutics during the third quarter worth $18,446,000. Finally, Baker BROS. Advisors LP boosted its position in Spyre Therapeutics by 59.6% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,000,000 shares of the company's stock valued at $16,760,000 after acquiring an additional 373,297 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该公司的持股。Wellington Management Group LLP 在第三季度将其在 Spyre Therapeutics 的持股比例提高了 8.4%。Wellington Management Group LLP 目前持有该公司 1,640,312 股股票，价值 27,492,000 美元，在此期间又购买了 126,834 股。Jefferies Financial Group Inc.在第二季度将其在 Spyre Therapeutics 的持股比例提高了 11.2%。Jefferies Financial Group Inc.目前持有该公司 1,388,854 股股票，价值 20,791,000 美元，在上个季度又购买了 140,000 股。Geode Capital Management LLC 在第二季度将其在 Spyre Therapeutics 的持股比例提高了 15.8%。Geode Capital Management LLC 目前持有该公司 1,227,232 股股票，价值 18,373,000 美元，在上个季度又购买了 167,669 股。TCG Crossover Management LLC 在第三季度购买了 Spyre Therapeutics 的新股份，价值 18,446,000 美元。最后，Baker BROS. Advisors LP 在第三季度将其在 Spyre Therapeutics 的持股比例提高了 59.6%。Baker BROS. Advisors LP 目前持有该公司 1,000,000 股股票，价值 16,760,000 美元，在上个季度又购买了 373,297 股。对冲基金和其他机构投资者持有公司 80.39% 的股票。</p>
</div><h2>About Spyre Therapeutics</h2>
<div class="lb-trans"><h2>关于 Spyre Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.</p>
<div class="lb-trans"><p>Spyre Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于癌症新型免疫疗法的发现和开发。该公司利用专有的蛋白质工程和生物制剂设计平台，创造旨在增强抗肿瘤免疫反应和抑制肿瘤生长的靶向分子。其临床前管线包括多个针对实体肿瘤和血液肿瘤适应症的候选疗法。</p>
</div><p>Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.</p>
<div class="lb-trans"><p>Spyre Therapeutics 由一支在蛋白质设计、免疫学和转化研究方面具有深厚专业知识的团队成立，致力于与领先的学术机构和研究组织合作，加速其发现工作。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Spyre Therapeutics</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Spyre Therapeutics</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 上市！100 美元的 IPO 前机会！</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1lSRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SYRE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Spyre Therapeutics 吗？</h2>
</div><p>Before you consider Spyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Spyre Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Spyre Therapeutics 并不在名单上。</p>
</div><p>While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Spyre Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

券商给予 Spyre Therapeutics, Inc.（纳斯达克股票代码：SYRE）“买入” 的平均评级